Mingyou Dong

Dr. Mingyou Dong

Youjiang Medical University for Nationalities, Baise City, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2025 in Pharmacological Research
Verified
Journal Article
Open access
FSFeng Shi
Feng Shi
GLGuang-Jing Li
Guang-Jing Li
YLYi Liu
Yi Liu
HZHai-Meng Zhou
Hai-Meng Zhou
YZYue Zhang
Yue Zhang
Xiao-Dong ZhangXiao-Dong Zhang
Xiao-Dong Zhang
Colorectal cancer (CRC) is characterized by a highly immunosuppressive tumor microenvironment, which limits the effectiveness of current immunotherapies. Identifying strategies to overcome this resistance is critical for improving treatment outcomes. In this study, we discovered that USP19 plays a pivotal role in regulating T-cell-mediated antitumor immunity through a CRISPR/Cas9 sgRNA library screen and co-culture assays with activated T cells. We demonstrated that USP19 deficiency significantly enhances the susceptibility to T cell-mediated cytotoxicity in CRC cells, organoids, and mouse models. Transcriptomic sequencing (RNA-seq) revealed activation of the PD-1 pathway in tumor with USP19-deficiency cells. Mechanistic investigations revealed that USP19 directly stabilizes PD-L1 by binding to its intracellular domain and preventing its degradation via K48-linked ubiquitination and proteasomal pathways. Clinically, USP19 expression was found to be significantly elevated in CRC tissues and was positively associated with PD-L1 levels, advanced tumor grade, poor differentiation, and TP53 mutations, highlighting its potential as a biomarker for aggressive CRC. Importantly, in vivo experiments demonstrated that targeting USP19, in combination with αPD-L1 therapy, synergistically suppressed CRC progression. This combination not only reduced PD-L1 levels but also enhanced CD8+ T-cell activation and GzmB infiltration, resulting in robust antitumor effects. These findings establish USP19 as a key driver of immune evasion in CRC and suggest that targeting USP19 could enhance the efficacy of immunotherapy, providing a promising new avenue for CRC treatment.

18 October 2023 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
WNWeihua Nong
Weihua Nong
GWGaomeng Wei
Gaomeng Wei
JWJunli Wang
Junli Wang
XLXiaocan Lei
Xiaocan Lei
JWJinyuan Wang
Jinyuan Wang
LHLiqiao He
Liqiao He

31 January 2025 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
WNWeihua Nong
Weihua Nong
HWHuimei Wei
Huimei Wei
SDSheng Dou
Sheng Dou
LHLiqiao He
Liqiao He
LLLuping Lin
Luping Lin
MDMingyou Dong
Mingyou Dong

1 September 2023 in Biochemical Genetics
Verified
Journal Article
Closed access
PDF file
LLLu-Sheng Liao
Lu-Sheng Liao
ZXZi-Jun Xiao
Zi-Jun Xiao
JWJun-Li Wang
Jun-Li Wang
TLTing-Jun Liu
Ting-Jun Liu
FHFeng-Die Huang
Feng-Die Huang
MDMingyou Dong
Mingyou Dong

4 August 2023 in Functional & Integrative Genomics
Verified
Journal Article
Closed access
PDF file
KCKeheng Chen
Keheng Chen
XZXin Zhang
Xin Zhang
HPHuixin Peng
Huixin Peng
FHFengdie Huang
Fengdie Huang
GSGuangyu Sun
Guangyu Sun
MDMingyou Dong
Mingyou Dong

28 January 2024 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
FHFeng-Die Huang
Feng-Die Huang
YZYan-Ping Zhong
Yan-Ping Zhong
GSGuang-Yu Sun
Guang-Yu Sun
QXQi-Jiang Xu
Qi-Jiang Xu
ZXZhi-Yong Xing
Zhi-Yong Xing
MDMingyou Dong
Mingyou Dong